Pharmacotherapy of myopic choroidal neovascularization

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients. Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents. Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy. Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.

Original languageEnglish (US)
Pages (from-to)4853-4859
Number of pages7
JournalCurrent pharmaceutical design
Issue number41
StatePublished - 2018


  • Aflibercept
  • Anti-vegf
  • Bevacizumab
  • Myopic choroidal neovascularization
  • Pegaptanib
  • Pharmacotherapy
  • Photodynamic therapy
  • Ranibizumab
  • Verteporfin

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Pharmacotherapy of myopic choroidal neovascularization'. Together they form a unique fingerprint.

Cite this